SPA
NBIX icon

Sherbrooke Park Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Sherbrooke Park Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,921
Closed -$399K – 824
2024
Q4 		$399K Sell
2,921
-2,389
-45% -$295K 0.13% 288
2024
Q3 		$612K Sell
5,310
-2,899
-35% -$397K 0.14% 236
2024
Q2 		$1.13M Buy
+8,209
New +$1.13M 0.2% 148

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sherbrooke Park Advisers's NBIX Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 2,921 shares — an estimated $399K sold.

Sherbrooke Park Advisers first reported a position in NBIX in Q2 2024 and held it in 3 quarters. The position peaked at $1.13M in Q2 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 2,921 Neurocrine Biosciences shares in Q1 2025, an estimated $399K.
  • Sherbrooke Park Advisers first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Neurocrine Biosciences position peaked at $1.13M in Q2 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.